Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Eylea Aflibercept Macular edema, central retinal vein occlusion List with clinical criteria and/or conditions Complete
Eylea Aflibercept Macular edema, branch retinal vein occlusion Reimburse with clinical criteria and/or conditions Complete
Eylea HD aflibercept 8mg/0.07mL diabetic macular edema Reimburse with clinical criteria and/or conditions Complete
Eylea HD aflibercept 8mg/0.07mL macular degeneration, age related Reimburse with clinical criteria and/or conditions Complete
Fabrazyme Agalsidase beta Fabry Disease Do not list Complete
Fabrazyme Agalsidase beta Fabry Disease Do not list Complete
Fampyra Fampridine Multiple sclerosis, improve walking disability Withdrawn
Fampyra Fampridine Multiple sclerosis, improve walking disability Do not list Complete
Fasenra benralizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete
Fasenra benralizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete